Skip to main content
BNTX
NASDAQ Life Sciences

CEO-affiliated entity files intent to sell $93.8M in BioNTech shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$109.38
Mkt Cap
$26.301B
52W Low
$81.2
52W High
$124.487
52W Position info
35% above low
Off High info
12% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

BNTX sits 35% above its 52-week low of $81.2 on light trading volume (0.3× avg).

Summary

Medine GmbH, an entity associated with CEO Ugur Sahin and listed as an officer and 10% stockholder, has filed a Form 144 indicating an intent to sell approximately $93.87 million worth of BioNTech SE shares.


Key Events · Ownership and Investor Activity · BNTX

  • Proposed Sale by CEO-Affiliated Entity

    Medine GmbH, an entity associated with CEO Ugur Sahin and identified as an officer and 10% stockholder, filed a Form 144 for the proposed sale of 858,209 shares.

  • Substantial Market Value

    The proposed sale has an approximate market value of $93.87 million, indicating a significant potential disposition of shares.

  • Prior Sales by CEO

    This filing follows previous sales by Ugur Sahin totaling $29.03 million over the past three months, as detailed in the filing, suggesting a pattern of insider selling.


Analysis · BNTX · Life Sciences

This Form 144 signals a substantial potential disposition of shares by Medine GmbH, an entity affiliated with BioNTech's CEO, Ugur Sahin, who is also identified as an officer and 10% stockholder. The proposed sale of over $93 million represents a notable transaction, especially following a series of positive strategic updates from the company in January. While a Form 144 is an intent to sell and not a guaranteed sale, such a large filing from a key insider can be perceived negatively by the market, suggesting a potential reduction in exposure by a significant stakeholder. This filing also follows prior sales by Ugur Sahin totaling over $29 million in the past three months. Investors will monitor subsequent Form 4 filings to confirm if and when these shares are actually sold.

At the time of this filing, BNTX was trading at $109.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.3B. The 52-week trading range was $81.20 to $124.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BNTX - Latest Insights

BNTX
Jul 20, 2026, 11:36 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $92.63
Real-time Price: $91.91 info
Change: -$0.720 (-0.78%) info
Market Cap: $23.379B info
BNTX
Jun 08, 2026, 8:01 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $87.85
Real-time Price: $91.91 info
Change: +$4.06 (+5%) info
Market Cap: $23.379B info
BNTX
Jun 01, 2026, 7:59 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $98.35
Real-time Price: $91.91 info
Change: -$6.44 (-7%) info
Market Cap: $23.379B info
BNTX
May 30, 2026, 2:15 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $97.04
Real-time Price: $91.91 info
Change: -$5.13 (-5%) info
Market Cap: $23.379B info
BNTX
May 22, 2026, 8:03 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $93.05
Real-time Price: $91.91 info
Change: -$1.14 (-1%) info
Market Cap: $23.379B info